Girish Mahajan (Editor)

Abemaciclib

Updated on
Edit
Like
Comment
Share on FacebookTweet on TwitterShare on LinkedInShare on Reddit
ATC code
  
None

Synonyms
  
LY2835219

PubChem CID
  
46220502

Legal status
  
Investigational

CAS Number
  
1231929-97-7

ChemSpider
  
29340700

Abemaciclib httpswwwmedchemexpresscomproductpichy1629

Fda breakthrough status for abemaciclib


Abemaciclib (previously known as LY2835219) is a CDK inhibitor selective for CDK4 and CDK6. It is an investigational drug for various types of cancer developed by Eli Lilly. It was designated as a breakthrough therapy by the U.S. Food and Drug Administration in October 2015.

Contents

Ongoing trial of abemaciclib and pembrolizumab in hr her2 negative breast cancer


Clinical trials

Successful Phase I and Phase II trials against breast cancer were announced in May and December 2014 respectively.

As of early 2016 Abemaciclib is involved in 3 Phase III clinical trials:

  • The JUNIPER Study is comparing Abemaciclib against Erlotinib in patients with stage IV Non-small-cell lung carcinoma
  • The MONARCH 2 study is investigating the effectiveness of Abemaciclib in combination with Fulvestrant for women with breast cancer. It is due to end in Feb 2017.
  • The MONARCH 3 study is investigating the effectiveness of Abemaciclib, plus either anastrozole or letrozole, as a first-line treatment for women with breast cancer. The trail is expected to end in June 2017.

    • Chemistry

    Abemaciclib may be synthesized in a 4 step manner using a Suzuki coupling, followed by a Buchwald–Hartwig amination with the final step being a reductive amination using the Leuckart reaction.

    References

    Abemaciclib Wikipedia
    (Text) CC BY-SA